Publication · Nov 2025
Science
Explore conditions, clinical trials, and the latest research.
These pages contain non-exhaustive scientific information about uses of products that have not yet been approved by regulatory authorities, as their efficacy and safety for these uses have not yet been established. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
Presentation · Sep 2025 · PDF
Acoramidis-HFSA-2025-VA-Incidence-of-ATTR-CM-by-State
Presentation · Sep 2025 · PDF
Acoramidis-HFSA-2025-Effect-on-CVM_Recurrent-CVH-Cumulative-Incidence-Oral-Presentation
Presentation · Sep 2025 · PDF
Acoramidis-HFSA-2025-Cardiac-Conduction-abnormalities
Publication · Sep 2025
Effect of acoramidis on recurrent and cumulative CV outcomes: ATTRibute-CM
Presentation · Aug 2025 · PDF
BBIO - Acoramidis TTR - ESC 2025 - Stable/Improved NAC at Month 30
Publication · Aug 2025
Contemporary oral medication use and frequency in ATTR-CM
Publication · Jul 2025
Unravelling the myriad physiologic roles of transthyretin
Publication · Jun 2025